Simple research view

BIIB · Biogen Inc.

$215.43 +2.23% Sep 10 close

Detected setup Trend Only · Setup Score 72/100

Stand aside — setup invalidated

Setup score 72, but distribution days reach 5 or more — stand aside until the condition resets.

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about BIIB

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$BIIB

Biogen Inc.

Biogen Inc. is a large-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $32B.

Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 3+

$215.43 latest close

⚠ Risk Signals

Bearish RSI Divergence Price higher high ($216.63→$221.56) but RSI lower high (70→66) — momentum diverging

Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.

Join to Watchlist $BIIB Share card

Verdict · setup score 72/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 72, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

No sourced report date Event risk is not modelled for this symbol

Deterministic evidence

BIIB+2.23%

Sector proxy · XLV-0.55%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. BIIB was +2.78 points vs XLV. +2.83 points vs SPY.

Session internals Strong momentum

Rule: closed up, at or above the open, in the top third of the day's range. Judged on internals, not on the size of the move.

Vs prior close+2.23% From the open+2.62% Range position84% GapNo gap

QQQ confirmationDiverging (-1.06%) SMH confirmationDiverging (-2.44%)

Short-term conviction -1 points.

QQQ, SMH moved against the stock — no index confirmation.

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $215.43 +2.2% Sep 10 close

52W High $225.80 4.6% below high

Wks Since High 0w

Base Depth 6.1% 7.5% today

RS Rank 49 percentile of scan

SMA 50 $209.33

Avg Vol 1,059,697

Rel Vol (Sep 10) 0.88×

More stats

52W Low $135.39

Tight Wks 0

Base B3

SMA 200 $191.72

RS Line vs High -4.2%

RS Line Slope +5.0% ▲

Group Rank #27/58

ADR% 2.4%

ATR(14) $5.69 (2.6%)

Vol Pace (live) N/A

U/D Vol 1.40

A/D Days 14A / 12D

A/D Rating B

VDU Bars 0/10 d

Power Trend 1d

Position in 52-week range 89thpercentile of the 52-week range

$135.39low

$225.80high

BIIB Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for BIIB.

Create Free Account

Technical Analysis Report Card

$BIIB · $215.43 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 68/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$209.33 ↑

100-day$201.98 ↑

200-day$191.72 ↑

Bullish (50 > 200)

RSI (14)

Reading51.4 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateWeakening

Histogram-1.056

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width43% · 8.7%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol1.4 · Neutral

Rel volume0.88×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $219.16swing level

R · $222.85swing level

R · $225.8052-week high

Price · $215.43now

S · $201.00swing level

S · $193.20swing level

S · $185.70swing level

Fibonacci · Uptrend swing

23.6% ◄ price here$212.31

38.2%$203.96

50.0%$197.22

61.8%$190.48

78.6%$180.87

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BIIB — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish

Want this read in a legend's voice? Ask a Legend about BIIB

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 6/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $215.43, MA150 $196.68, MA200 $191.72

1.2 150-day MA > 200-day MAMA150 $196.68 vs MA200 $191.72

Failing evidence

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 57

2. Quarterly EPS growth ≥ 25%+0.8% QoQ

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

N: Near 52-week high or RS line new high4.6% below high | RS line new high: False

S: Base tightness (ATR% ≤ 4.5%)ATR% 2.64%

Failing evidence

C: Quarterly EPS acceleration ≥ 25%+0.8% QoQ

L: RS rank ≥ 80 (IBD leadership)RS rank 57

2/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $215.43 vs MA200 $191.72

Failing evidence

Volume expansion above averageVolume ratio 0.88x

Relative strength ≥ 60RS 57

5/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$215.43

Distance from 52-week high4.6% below high

Failing evidence

Relative strengthRS 57

Volume vs average0.88x

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$215.43

Distance from 52-week high4.6% below high

Failing evidence

Relative strengthRS 57

Volume vs average0.88x

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$215.43

Distance from 52-week high4.6% below high

Failing evidence

Relative strengthRS 57

Volume vs average0.88x

3/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -4 B

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met

C 3/7 criteria

Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ +1%

✗ Revenue growth ≥20% YoY +0%

✓ Gross margin ≥30% 74%

✗ ROE ≥17% 5%

✗ RS rating ≥80 (leadership) 57

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -4.6%

Method Playbook

Trade it like O'Neil EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.

Pivot

Pro level

Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Trend Only

72 setup score

RS Score 57

Trend template 7/8

Why This Setup? D+W Confluence

Trend Only · schematic

Gatekeeper 7/8 | Strong trend (7/8) | Stage 2

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met

A relative-strength leader — not met RS rank 49 — laggard
Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Clear of earnings — partly met Report date unknown
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.9× average — light
In a confirmed uptrend — met Stage 2 · Trend template 7/8

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $215.43 vs SMA150 $196.68 / SMA200 $191.72

SMA 150 above SMA 200 SMA150 $196.68 vs SMA200 $191.72

SMA 200 trending up Slope +5.94 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $209.33

Price above SMA 50 $215.43 vs SMA50 $209.33

30%+ above 52-week low +59.1% from $135.39

Within 25% of 52-week high -4.6% from $225.80

RS score above 70 RS 57

Fundamentals

52W Range

89%

Mkt Cap SEC

31.6B

EPS QoQ

+1%

Rev YoY

+0%

ROE

Gross Margin

74%

D/E

0.34

EPS TTM

$5.65

P/E TTM

38.2x

Float

147M

Company

Company profile

Biogen Inc.

BIIB · NASDAQ · Health Technology · Pharmaceuticals: Major

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$168.64

W. Resist

$225.80

W. Patterns

Base Breakout

Weekly Structure

Trend Neutral

Tight Weeks 0

Confirmation Neutral

Scan History

20× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Trend Only ✓ Gate

69 0.0%

Sep 09

Trend Only ✓ Gate

71 +2.2%

Get the full picture on BIIB

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial